Lucentis ranibizumab: Phase III started

Roche disclosed that last quarter its Genentech Inc. unit and Novartis began the Phase III HARBOR trial to evaluate 0.5 and 2 mg intravitreal injections of Lucentis in 1,110 patients. Genentech and No...